Since the awarding of its first NCI Grant in 1987, the University of Texas M.D. Anderson Cancer Center Community Clinical Oncology Program (MDACCOP) Research Base has managed 150 clinical trials involving more than 5,000 patients, including 2,688 patients entered onto chemoprevention trials. The MDACCOP Research Base will continue to generate and support a spectrum of clinical studies of cancer control, prevention and therapy that can be implemented and conducted efficiently in a community environment. The Research Base and its affiliated CCOP sites have the full support and institutional resources, including the clinical research infrastructure, of the MDACC, the world?s largest and highest ranked comprehensive cancer center. The following specific aims are proposed: 1. Provide affiliate CCOPs and MBCCOPs access to MDACC clinical trials. 2. Transfer information, technology, and standards from the academic centers to the community. 3. Enhance the development of prevention and control trials that include behavioral interventions, chemoprevention trials, symptom control, the identification of individuals at increased risk for cancer or recurrence of their cancer, and the development of health outcomes research in the community setting. 4. Integrate the Gynecology Oncology Group (GOG) CCOPs into the MDACCOP RB; enable the current MDACCOPs to access the GOG studies and affiliate with another RB (as a 5th affiliate). 5. Develop new methodologies for answering cancer control questions in a multi-institutional setting, such as remote symptom assessment, and establish the educational support systems for initiation of these studies in the community. 6. Provide strategies to increase the recruitment of members of minority groups and women for clinical and cancer control trials. 7. Maintain a comprehensive data management system that links MDACC to the affiliate CCOPs and MBCCOPs. This system ensures the accurate collection and transmission of information for research trials and provides a facility to enhance ongoing quality assurance, data monitoring, and on-site audits. 8. Work with the NCI Community Oncology and Prevention Trials Research Group to ensure the research programs of the RB are congruent with the goals of the national program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Public Health & Prev Medicine
Other Domestic Higher Education
United States
Zip Code
Levin, Victor A; Ictech, Sandra E; Hess, Kenneth R (2018) Clinical importance of eflornithine (?-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol 7:CNS16
Narayan, Hari K; Wei, Wei; Feng, Ziding et al. (2017) Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart 4:e000524
Spencer, Christine N; Lopez, Gabriel; Cohen, Lorenzo et al. (2016) Nurse and patient characteristics predict communication about complementary and alternative medicine. Cancer 122:1552-9
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76
Penas-Prado, Marta; Hess, Kenneth R; Fisch, Michael J et al. (2015) Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17:266-73

Showing the most recent 10 out of 43 publications